• Nicox Resubmits AC-170 (Zerviate) NDA to the U.S. FDA drugs.com
    March 13, 2017
    Nicox S.A. announced the resubmission of the New Drug Application (NDA) for AC-170, its novel, proprietary, cetirizine eye drop formulation for the treatment of ocular itching associated with allergic conjunctivitis.
PharmaSources Customer Service